Pancreatic Cancer Research

Clinical trialPhase 1 / Phase 2Completed

XB2001 in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic Cancer

A Phase I/II Randomized, Double-blind, Placebo-controlled Trial (1-BETTER) Examining XB2001 (Anti-IL-1⍺ True Human Antibody) in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic Cancer

Outcome
Results posted; no analysis attached
Phase
Phase 1 / Phase 2
Status
Completed
Study type
Interventional
Start
27 May 2021
Ended
10 June 2025
Enrollment
76 participants
Sites
30
Primary outcomes
To Establish the Maximum Tolerated Dose (MTD) of XB2001 as Measured by Dose-Limiting Toxicity (DLT), in Combination With ONIVYDE + LV + 5-FU Chemotherapy Regimen in Patients With Advanced Pancreatic Cancer.; Safety and Tolerability of XB2001 in Combination With ONIVYDE + LV + 5-FU
Sponsor type
Industry
Results posted
4 August 2026
Last update
4 August 2026

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Results

Primary endpoint
Results posted; no analysis attachedAs posted on ClinicalTrials.gov ↗, registry record of 4 August 2026
DLT/MTD
To Establish the Maximum Tolerated Dose (MTD) of XB2001 as Measured by Dose-Limiting Toxicity (DLT), in Combination With ONIVYDE + LV + 5-FU Chemotherapy Regimen in Patients With Advanced Pancreatic Cancer.Phase I: XB2001 250 mg: 0 of 3Phase I: XB2001 500 mg: 0 of 5Phase I: XB2001 1000 mg: 0 of 3Phase II: XB2001 1000 mg: 0 of 0Phase II: Placebo 1000 mg: 0 of 0Values: ParticipantsTime frame: 28 days (consisting of the first two 14-day treatment cycles or the formal DLT observation window).No analysis posted for this outcome (outcome 1)
Primary outcome
Safety and Tolerability of XB2001 in Combination With ONIVYDE + LV + 5-FUPhase I: XB2001 250 mg: 0 of 0Phase I: XB2001 500 mg: 0 of 0Phase I: XB2001 1000 mg: 0 of 0Phase II: XB2001 1000 mg: 32 of 33Phase II: Placebo: 32 of 32Values: ParticipantsTime frame: From post-infusion visit 1(week 0) through visit 13 (week 24), which is two weeks after the last infusion.No analysis posted for this outcome (outcome 2)
Participants
Phase I: XB2001 250 mg: 3 started, 3 completedPhase I: XB2001 500 mg: 5 started, 3 completedPhase I: XB2001 1000 mg: 3 started, 3 completedPhase II: XB2001 1000 mg: 33 started, 9 completedPhase II: Placebo 1000 mg: 32 started, 8 completed
Serious adverse events
Phase I: XB2001 250 mg: 1 of 3Phase I: XB2001 500 mg: 1 of 5Phase I: XB2001 1000 mg: 0 of 3Phase II: XB2001 1000 mg: 10 of 33Phase II: Placebo 1000 mg: 14 of 32Participants with at least one serious adverse event, of those at risk, as posted
9 secondary outcomes, the first 8 shown
PFS · Progression Free Survival (PFS)
Phase II: XB2001 1000 mg 111 (79 to NA), n=33; Phase II: Placebo 1000 mg 62 (56 to 179), n=32 [median Days, 95% Confidence Interval]
OS · Overall Survival (OS)
Phase II: XB2001 1000 mg 290 (138 to 407), n=33; Phase II: Placebo 1000 mg 221 (164 to 307), n=32 [median Days, 95% Confidence Interval]
ORR · Objective Response Rate (ORR)
Phase II: XB2001 1000 mg 9.1 (3.14 to 23.57), n=33; Phase II: Placebo 1000 mg 6.3 (1.73 to 20.15), n=32 [percentage of responders, 95% Confidence Interval]
Time to Treatment Failure(TTF)
Phase II: XB2001 1000 mg 76 (55 to 111), n=33; Phase II: Placebo 1000 mg 57 (52 to 167), n=32 [median Days, 95% Confidence Interval]
Number of Serious Adverse Events (SAEs)
Phase II: XB2001 1000 mg 10, n=33; Phase II: Placebo 1000 mg 14, n=32 [participants]
Incidence of Grade 3-4 Diarrhea
Phase II: XB2001 1000 mg 3, n=33; Phase II: Placebo 1000 mg 7, n=32 [Number of events]
Duration of Hospitalization
Phase II: XB2001 1000 mg 80, n=33; Phase II: Placebo 1000 mg 120, n=32 [Days]
Plasma Concentration of Natrunix
Phase I: XB2001 250 mg 71.8 (9.7), n=3; Phase I: XB2001 500 mg 151.7 (20.9), n=3; Phase I: XB2001 1000 mg 315.4 (11.8), n=3; Phase II: XB2001 1000 mg 200 (132), n=16; Phase II: Placebo 1000 mg 0 (0), n=32 [mean microgram/mililitre, Standard Deviation]

Every value is copied from the trial’s results record at ClinicalTrials.gov. “Statistically significant” describes the posted test only: it does not say which group did better, and nothing here is read from a paper.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

This trial will include 2 portions (phase 1 and phase 2). The first portion will be a Phase I, open label, dose escalation study to establish the maximum tolerated dose (MTD) of XB2001 as measured by Dose-Limiting Toxicity (DLT), in combination with ONIVYDE + LV + 5-FU chemotherapy regimen in patients with advanced pancreatic cancer and to determine the recommended dose for the subsequent Phase 2 study. The phase 2 portion will be implemented with the maximum established tolerated dose (MTD) of XB2001. The target enrollment in the phase 2 portion is 60 patients which will be randomized on a 1:1 basis to XB2001 plus ONIVYDE + LV + 5-FU (Arm 1) or placebo plus ONIVYDE + LV + 5-FU (Arm 2).

Detailed description public domain (ClinicalTrials.gov)

Study Title: A Phase I/II randomized, double-blind, placebo-controlled trial (1-BETTER) examining XB2001 (anti-IL-1⍺ True Human antibody) in combination with ONIVYDE + 5-FU/LV (+folinic acid) in advanced pancreatic cancer Sponsor: XBiotech USA, Inc. Sample Size: Approximately 69 patients will be enrolled in the USA (at least 9 patients in the open label phase 1 portion and 60 patients in the randomized phase 2 portion) Approximate Duration: This trial will include 2 phases. The first portion will be a Phase I, open label, dose escalation study evaluating the safety, tolerability and establishing the Maximum Tolerated Dose (MTD) of XB2001 in at least nine patients with metastatic pancreatic adenocarcinoma who are receiving ONIVYDE + Leucovorin l + d racemic + 5-Fluorouracil chemotherapy treatment. The duration for each patient in the Phase I portion will be 14 days (1 treatment cycle) in which they will be given one intravenous dose of XB2001 prior to receiving ONIVYDE + Leucovorin l + d racemic + 5-Fluorouracil chemotherapy treatment and assessed for Dose Limited Toxicities (DLT). The Phase II portion will be implemented following the completion of the Phase I portion and declaration of the MTD. The duration of subject participation in the randomized, double-blind, placebo-controlled Phase II portion of the trial is approximately 28 weeks: including a screening period of up to 30 days, and 24-week treatment period. All study subjects can continue treatment with XB2001 in an open label extension, for as long as they are judged to be benefitting clinically and have had no unacceptable toxicities.

Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)

To Establish the Maximum Tolerated Dose (MTD) of XB2001 as Measured by Dose-Limiting Toxicity (DLT), in Combination With ONIVYDE + LV + 5-FU Chemotherapy Regimen in Patients With Advanced Pancreatic Cancer. [28 days (consisting of the first two 14-day treatment cycles or the formal DLT observation window).]. Count Of Participants, Participants. Phase I: XB2001 250 mg (n=3): 0; Phase I: XB2001 500 mg (n=5): 0; Phase I: XB2001 1000 mg (n=3): 0; Phase II: XB2001 1000 mg (n=0): 0; Phase II: Placebo 1000 mg (n=0): 0.

Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)

Safety and Tolerability of XB2001 in Combination With ONIVYDE + LV + 5-FU [From post-infusion visit 1(week 0) through visit 13 (week 24), which is two weeks after the last infusion.]. Count Of Participants, Participants. Phase I: XB2001 250 mg (n=0): 0; Phase I: XB2001 500 mg (n=0): 0; Phase I: XB2001 1000 mg (n=0): 0; Phase II: XB2001 1000 mg (n=33): 32; Phase II: Placebo (n=32): 32.

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Progression Free Survival (PFS) [From baseline until the date of first documented disease progression or date of death (from any cause), whichever come first.]. Median, Days (95% Confidence Interval). Phase II: XB2001 1000 mg (n=33): 111 (79 to NA) [The upper limit of the confidence interval could not be estimated within the study period, as the 168-day cutoff was reached before a sufficient number of events occurred in the Natrunix group. Although the median survival was reached at 111 days, the high proportion of censored observations (51.5%) precluded estimation of the upper confidence limit, as the survival probability did not fall below the 50% threshold within the available follow-up period.]; Phase II: Placebo 1000 mg (n=32): 62 (56 to 179).

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Overall Survival (OS) [From baseline until death from any cause]. Median, Days (95% Confidence Interval). Phase II: XB2001 1000 mg (n=33): 290 (138 to 407); Phase II: Placebo 1000 mg (n=32): 221 (164 to 307).

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Objective Response Rate (ORR) [Analyses performed at Visit 5 (Week 8), Visit 9 (Week 16), and Visit 13 (Week 24). This outcome measure was reported for Visit 13.]. Number, percentage of responders (95% Confidence Interval). Phase II: XB2001 1000 mg (n=33): 9.1 (3.14 to 23.57); Phase II: Placebo 1000 mg (n=32): 6.3 (1.73 to 20.15).

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Time to Treatment Failure(TTF) [From baseline until treatment failure assessed up to Visit 13 (Week 24)]. Median, Days (95% Confidence Interval). Phase II: XB2001 1000 mg (n=33): 76 (55 to 111); Phase II: Placebo 1000 mg (n=32): 57 (52 to 167).

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Number of Serious Adverse Events (SAEs) [From post-infusion visit 1(week 0) through visit 13 (week 24), which is two weeks after the last infusion.]. Number, participants. Phase II: XB2001 1000 mg (n=33): 10; Phase II: Placebo 1000 mg (n=32): 14.

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Incidence of Grade 3-4 Diarrhea [From post-infusion visit 1(week 0) through visit 13 (week 24), which is two weeks after the last infusion.]. Number, Number of events. Phase II: XB2001 1000 mg (n=33): 3; Phase II: Placebo 1000 mg (n=32): 7.

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Duration of Hospitalization [From post-infusion visit 1(week 0) through visit 13 (week 24), which is two weeks after the last infusion.]. Number, Days. Phase II: XB2001 1000 mg (n=33): 80; Phase II: Placebo 1000 mg (n=32): 120.

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Plasma Concentration of Natrunix [Reported results Natrunix: Phase I: V1 post-dose collected at 30 min post-infusion at visit 1(Week 0), which represents Cmax of Cycle 1. Phase II: V6 pre-dose, at Visit 6 (Week 10), represents the trough of steady state concentration.]. Mean, microgram/mililitre (Standard Deviation). Phase I: XB2001 250 mg (n=3): 71.8 (9.7); Phase I: XB2001 500 mg (n=3): 151.7 (20.9); Phase I: XB2001 1000 mg (n=3): 315.4 (11.8); Phase II: XB2001 1000 mg (n=16): 200 (132); Phase II: Placebo 1000 mg (n=32): 0 (0).

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Number of Treatment Cycles [From randomization to end of study or study discontinuation for any reasons, up to 24 weeks]. Number, Number of dose. Phase II: XB2001 1000 mg (n=33): 199; Phase II: Placebo 1000 mg (n=32): 190.